

Synthesis of furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine derivatives and their antibacterial activity

Ivana Zemanová,^a Renata Gašparová,^{a*} Filip Kraic,^c Dáša Kružlicová,^a Tibor Maliar,^b Andrej Boháč,^d and Gabriela Addová^e

^a Department of Chemistry and ^b Department of Biotechnologies, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Námestie. J. Herdu 2, 917 01 Trnava, Slovak Republic

^c Saneca Pharmaceuticals, Nitrianska 100, 920 01 Hlohovec, Slovak Republic

^d Department of Organic Chemistry and ^e Institute of Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovičova 6, 842 15 Bratislava, Slovak Republic

E-mail: renata.gasparova@ucm.sk

Received 07-08-2016

Accepted 04-27-2017

Published on line 05-14-2017

Abstract

Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones **5** were synthesized either by reaction of carbohydrazone **2** with triethyl orthoesters or by acetylation of methyl 4*H*-furo[3,2-*b*]pyrrole-5-carboxylate **1** followed by thionation of 4-acetylfuro[3,2-*b*]pyrrole-5-carboxylate **3** and cyclisation of thione **4** with hydrazine. Triazine **5a** afforded the corresponding thione **7** by reaction with P₂S₅. Upon reaction with alkyl- or acylhalogenides compounds **5** and **7** gave *N*(7)-substituted products **6** and **8**, respectively. Finally, triazino-triazinone derivative **9** was synthesized by cyclisation of thione **8b** with hydrazine. Compounds **5** - **9** were evaluated for their antibacterial activity.



Keywords: Furo[3,2-*b*]pyrrole, triazine, orthoester, cyclisation, thione, antibacterial activity

Introduction

The synthesis and the study of physical and chemical properties of pyrrolo-fused heteroaryl compounds, such as furo-, thieno- and selenopyrroles has been well documented over the last few decades. Furo[3,2-*b*]pyrroles are isosteres of the indole ring system in which the benzene ring is replaced by the furan ring. Efficient synthetic routes to these heterocycles are of great interest¹⁻⁴ as the furo[3,2-*b*]pyrrole core has been found in compounds with diverse biological activities⁵⁻⁷ or they are used as the fluorescent dyes⁸.

Heterocyclic compounds containing five- and six-membered nitrogen heterocyclic rings have also attracted the attention due to the fact that they exhibit many biological interactions^{9,10}. In addition, 1,2,4-triazin-6-one is structural system found in numerous natural and synthetic biologically active compounds with a wide range of biological activities including anti-inflammatory,¹¹ antifungal,¹⁰ antiviral,¹² anti-HIV¹³ or anticonvulsant.¹⁴


Among tricyclic 5-5-6 fused ring heterocycles only thieno[3,2-*b*]pyrrole[3,2-*d*]pyridazinones and pyrimidinones¹⁵ and furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones¹⁶ have been synthesized and only these thieno-derivatives were evaluated for their anticancer activity. Therefore we are interested in the chemistry of the 1,2,4-triazine ring fused on its 4-5 bond with furo[3,2-*b*]pyrrole system. In our continuing efforts towards the synthesis and biological activity of furo[3,2-*b*]pyrrole derivatives we are interested in a synthesis of 5- and 7-substituted furo[3,2-*b*]pyrrole derivatives fused with six-membered heterocyclic ring and their antibacterial activity against selected strains of G⁺ and G⁻ bacteria.

Results and Discussion

Generally, the construction of 1,2,4-triazin-6-one moiety can be reached by two main strategies. The first one is based on the cyclocondensation of α -aminocarbohydrazide with an orthoester.^{16,17} The second method involves the cyclisation of *N*-thioacyl- α -aminoester with hydrazine.¹⁸

The title compounds **5** are well accessible^{16,19} from methyl 4*H*-furo[3,2-*b*]pyrrole-5-carboxylate **1** *via* its transformation to carbohydrazide **2**. Hydrazinolysis was achieved in 80% yield by heating of **1** with hydrazine hydrate in ethanol for 20h¹⁶. Subsequently, the construction of 1,2,4-triazine ring of **5** was taken place by the cyclization of **2** with orthoesters (triethyl orthoformate, triethyl orthochloroacetate or triethyl orthoacetate) (Scheme 1, path a) in dimethylformamide. Resulting furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones **5a-5c** were obtained in 69-75% yields. Compounds **5a – 5c** display in their ¹H NMR spectra the singlet at 11.65-12.09 ppm due to NH group. The H-2 and H-9 protons resonate as doublets at 8.00-7.97 ppm (*J* = 2.1 Hz) and 6.88-7.17 ppm (*J* = 2.4 Hz) regions, respectively. IR Spectra of **5a-5c** exhibit absorption band of C-8 carbonyl group at 1639-1642 cm⁻¹. ¹³C NMR spectra of **5a-5c** display the C-8 carbonyl carbons in the region 154.4-155.2 ppm and C-5 carbons at 138.2-148.4 ppm.

In order to exploit the new route to the formation of triazine ring of **5c**, we have realized *N*-acetylation of **1** by method of Krutošiková²⁰ in acetic anhydride for 4 h, when methyl *N*-acetylfuro[3,2-*b*]pyrrole-5-carboxylate **3** was obtained in 60% yield. Compound **3** was subsequently converted to the corresponding thione **4** in 60% yield by reaction with phosphorus pentasulfide in pyridine for 10 h. Finally, thione **4** cyclised into **5c** in 65% yield by heating with hydrazine hydrate in ethanol (Scheme 1, path b).




Scheme 1. Synthesis of triazine derivatives **5**

Although the yields of **5c** by the *path b* (65%) and the *path a* (71%), were comparable, *path b* requires long reaction time (168h) and this fact limits the applicability of this approach.

Compound **3** displays in its ¹H NMR spectrum doublet due to H-2 proton at 7.79 ppm (*J* = 2.4 Hz), doublet of doublets of the pyrrole H-6 proton at 6.76 ppm (*J* = 2.4, 0.9 Hz) and doublet of the H-3 proton at 6.61 ppm (*J* = 2.4, 0.9 Hz). The most distinct signals of **3** in the ¹³C NMR spectrum were the carbonyl carbons at 168.9 and 162.1 ppm.

Alkylation of triazine **5a** with alkylhalides (CH₃I, n-C₆H₉Br, ClCH₂COOEt) in dimethylformamide in the presence of sodium hydride at room temperature for 2.5-6 h provided 7-alkyl[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones **6a**, **6b** and **6d** in 45-72% yields (Scheme 2). Synthesis of 7-benzyl[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one **6c** required higher temperature (55 °C) and the derivative **6c** was obtained in low yield (27%) after heating overnight. 7-Acetylated compound **6e** was synthesized in 53% yield by refluxing of **5a** in acetic anhydride for 1.5h.

The structures of compounds **6a-6e** were established by ¹H NMR, ¹³C NMR and IR spectroscopy. They display in their ¹H NMR spectra, in addition to other signals, singlets of H-5 protons at 8.81-8.83 ppm, doublets of the pyrrole H-2 protons in the region of 7.99-8.09 ppm (*J* = 2.4 Hz), H-3 protons resonate as doublets of doublets at 7.09-7.11 ppm (*J* = 2.1, 0.9 Hz). The H-9 protons appear as singlets at 7.14-7.20 ppm. ¹³C NMR spectra show the signals of C-8 carbonyl carbons at 153.9-154.6 ppm, region, signals of C-5 carbon at 149.7-151.6 ppm region. In the spectrum of **6e** there is the signal of the carbonyl carbon of acetyl group at 170.6 ppm and carbonyl carbon of methoxycarbonyl group of **6d** appears at 168.2 ppm. The characteristic bands observed at 1641-1652 cm⁻¹ in IR spectra correspond to the C=O groups at C-8.



Scheme 2. Synthesis of triazines **6-8** and triazino-triazinone **9**.

The carbonyl group at C-8 of triazine ring of **5a** can be easily thionated^{1,16} by reaction with phosphorus pentasulfide in pyridine to give thione **7** in high yield (85%). Subsequent reaction of **7** with methyl iodide in dimethylformamide in the presence of sodium hydride at room temperature for 1h led to 7-methylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine-8(7*H*)-thione **8a** in 76% yield. Synthesis of **8a** as well as **8b** was also achieved from N(7)-substituted derivatives **6a,6d** which were thionated with P₂S₅ in pyridine for 5-9h. The yield of **8a** was slightly lower (67%) in comparison to the inverse reaction sequence and thione **8b** was synthesized in 71% yield (Scheme 2).

The structures of compounds **7** and **8** were established by ¹H NMR, ¹³C NMR and IR spectroscopy. ¹H NMR spectra show doublets of H-5 protons at 10.98-9.16 ppm region (*J* = 0.6 Hz), doublets of the pyrrole H-2 protons in the region of 8.09-8.31 ppm (*J* = 2.1 Hz), H-3 protons resonate as doublets of doublets at 7.15-7.34 ppm (*J* = 2.1, 0.9 Hz). The H-9 protons appear as singlets at 7.76-7.29 ppm. ¹³C NMR spectra show the signals of C-8 thione carbons at 160.3-173.3 ppm and signals of C-5 carbon at 144.8-150.9 ppm. The characteristic band observed at 1257 cm⁻¹ in IR spectrum of **7** corresponds to the C=S group at C-8.

The presence of thione and methyl-carboxylate groups in **8b** enables the cyclisation with hydrazine to afford 2*H*-furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazino[3,4-*f*][1,2,4]triazine-3(4*H*)-one **9** in 64% yield after 140h heating in ethanol. ¹H NMR spectrum shows singlets of H-5 and H-12 protons at 8.79 and 7.17 ppm, respectively. Doublet of H-2 proton appears at 8.01 ppm (*J* = 2.1 Hz) and doublet of doublets of H-3 proton is at 7.11ppm (*J* = 2.4, 0.9 Hz). ¹³C NMR spectrum shows the signals of C-9 carbonyl group at 160.6 ppm and signal of C-5 carbon at 154.3 ppm.

Antibacterial activity. Compounds **2, 3, 5a, 5c, 6a, 6b, 6c, 6d, 7, 8a, 8b** and **9** were screened on their antibacterial activity on G⁻ bacterial species *Escherichia coli* CCM 7929, *Pseudomonas syringae* CCM 2114 and G⁺ bacterial species *Micrococcus luteus* CCM 732, *Bacillus pumilus* CCM 2218. Antibacterial activity of all tested structures has been compared to standard 6-aminopenicillanic acid (6-APA) as known building block of successful antibiotics – penicillins. The result of antibacterial activity is presented in Table 1.

Table 1. Antibacterial activity of standard 6-APA and compounds furo[3,2-*b*]pyrroles **2** - **8** on G⁻ bacterial species (*Escherichia coli* CCM 7929, *Pseudomonas syringae* CCM 2114) and G⁺ bacterial species (*Micrococcus luteus* CCM 732, *Bacillus pumilus* CCM 2218).

Compound	MIC/ (mM)			
	<i>M. luteus</i>	<i>B. pumilus</i>	<i>E. coli</i>	<i>P. syringae</i>
6-APA	4.00	7.3	3.2	5.82
2	3.84	5.12	15.36	10.24
3	0.64	5.12	10.24	2.56
5a	0.016	3.2	1.28	1.28
5c	2.56	2.56	2.56	2.56
6a	0.024	20.48	12.88	3.84
6b	1.92	2.56	2.56	2.56
6c	20.48	20.48	20.48	20.48
6d	0.64	10.24	10.24	1.6
7	15.36	20.48	15.36	15.36
8a	>20.48	>20.48	>20.48	>20.48
8b	12.24	20.48	12.24	20.48
9	>20.48	>20.48	>20.48	>20.48

As it is shown in Table 1, only compounds **5a**, **5c** and **6b** exhibit higher antibacterial activity than standard 6-APA on all bacterial strains with MIC values in the range 0.016 - 2.56 mM. Moderate antibacterial activity against *Micrococcus luteus* has been observed for compounds **5a** and **6a** (MIC values 0.016 and 0.024 mM, respectively) and compounds **3** and **6d** showed poor antibacterial activity against *Micrococcus luteus* with MIC value 0.64 mM.

From structural point of view, compounds with lower molecular weight expressed a higher measure of antibacterial activity and the derivatization of the N-7 nitrogen atom of triazine ring has been concluded as counter-productive in relation to antibacterial activity. According to Lipinski's rule of five^{21,22} the trend of increasing antibacterial activity indicates the predominance of the hydrogen bond acceptors over the hydrogen bond donors, comparing the results between compounds **2** and **3**. As it is shown in Table 1, all tested compounds were more effective on two G⁺ bacterial species (*M. luteus* and *B. pumilus*) than on G⁻ bacterial targets (*E. coli* and *P. syringae* CCM 2114), what is typical for inhibitors of bacterial cell wall peptidoglycan synthesis like β -lactam antibiotics.

Experimental Section

General. Melting points of products were determined on a Kofler hot plate apparatus and are uncorrected. ¹H NMR / ¹³C NMR spectra were obtained on a 300 MHz/75 MHz spectrometer VARIAN GEMINI 2000 in DMSO-d₆ with tetramethylsilane as the internal standard. The infrared spectra were taken on a FTIR IRAffinity-1 spectrophotometer using KBr technique. Elemental analyses were performed on FlashEA 2000 CHNS/O-OEA analyser. MS spectra were measured at Agilent Technologies 1200 Series apparatus. All solvents were distilled and dried appropriately prior to use. The course of reactions was monitored by TLC in ethyl acetate –hexane. Methyl 4*H*-furo[3,2-*b*]pyrrole-5-carboxylate (**1**), 4*H*-furo[3,2-*b*]pyrrole-5-carbohydrazide (**2**), furo[2',3':4,5]

pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (**5a**), and furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine-8(7*H*)-thione (**7**) were synthesized following the published procedures^{1,16}. The other chemicals were purchased from the suppliers as the highest purity grade. Bacteriological thermostat BT 120 (Czech Republic) was used to the cultivation of samples. All bacterial species it has been purchased from Czech Collection of Microorganisms - CCM (Brno, Czech Republic). Microplates have been purchased from VWR, Inc. (Vienna, Austria).

Methyl 4-ethanethioyl-4*H*-furo[3,2-*b*]pyrrole-5-carboxylate (4**).** A solution of methyl 4-acetyl-4*H*-furo[3,2-*b*]pyrrole-5-carboxylate **3** (1.48 g, 7.14 mmol) and P₂S₅ (2.38 g, 10.7 mmol) in pyridine (20 mL) was refluxed for 10h. The mixture was cooled, diluted with water (30 mL) and extracted with chloroform (2 x 15 mL). The extract was dried over MgSO₄, evaporated and the residue was crystallized from dimethylformamide to give **4** as yellow powder. Yield 60%, mp > 350 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.65 (d, 1H, *J* 2.7 Hz, H-2), 7.98 (t, 1H, *J* 2.9, 0.9 Hz, H-6), 7.54 (dd, 1H, *J* 2.7, 0.9 Hz, H-3), 3.45 (s, 3H, CH₃), 3.17 (s, 3H, CH₃). The ¹³C NMR spectrum was unmeasurable because of the low solubility of **4**. Anal. Calcd. for C₁₀H₉NO₃S (223.25) C 53.80, H 4.06, N 6.27, S 14.36. Found: C 53.48, H 4.01, N 5.89, S 14.22%.

Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones (5a** – **5c**). Method A.** A mixture of 4*H*-furo[3,2-*b*]pyrrole-5-carbohydrazide **2** (0.52g, 3.1 mmol) and triethyl orthoformate (0.46g, 3.1 mmol) was refluxed in dry dimethylformamide (3 mL) for 3.5h (for **5b**: 80 °C, 24h). The solution was cooled and the precipitate was filtered off and crystallized from dioxane.

Method B. To the solution of methyl 4-ethanethioyl-4*H*-furo[3,2-*b*]pyrrole-5-carboxylate **4** (0.4 g, 1.9 mmol) in ethanol (15 mL) was added hydrazine hydrate (2.7 g, 86 mmol). The mixture was heated at 80 °C for 168h. The work-up was the same as in Method A.

Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (5a**).**¹⁵ White solid, yield 69%, mp 284-286 °C. IR (KBr) ν/cm⁻¹ 3114 (NH), 1641 (C=O). ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.81 (s, 1H, NH), 8.75 (s, 1H, H-5), 8.00 (d, 1H, *J* 2.4 Hz, H-2), 7.14 (s, 1H, H-9), 7.11 (dd, 1H, *J* 2.4, 0.8 Hz, H-3); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 155.2, 149.5, 148.4, 127.7, 124.8, 123.5, 100.0, 92.4. MS (ES): *m/z* 176.1 (MH⁺). Anal. Calcd. for C₈H₅N₃O₂ (175.14) C 54.86, H 2.88, N 23.99. Found: C 54.69, H 2.93, N 24.16%.

5-(Chloromethyl)furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (5b**).** White solid, yield 75%, mp 224-226 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.09 (s, 1H, NH), 7.97 (d, 1H, *J* 2.1 Hz, H-2), 6.88 (d, 1H, *J* 2.7 Hz, H-9), 6.67 (dd, 1H, *J* 2.1, 0.6 Hz, H-3), 5.09 (s, 2H, CH₂). The ¹³C NMR spectrum was unmeasurable because of the low solubility of **5b**. Anal. Calcd. for C₉H₆ClN₃O₂ (223.62) C 48.34, H 2.70, N 18.79. Found: C 48.02, H 2.73, N 18.61%.

5-Methylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (5c**).** White solid, yield 71% (A¹¹), 65% (B), mp 258-261 °C. IR (KBr) ν/cm⁻¹ 3126 (NH), 1633 (C=O). ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.65 (s, 1H, NH), 7.99 (d, 1H, *J* 2.1 Hz, H-2), 7.15 (dd, 1H, *J* 2.4, 0.8 Hz, H-3), 7.10 (d, 1H, *J* 2.4 Hz, H-9), 2.60 (s, 3H, CH₃); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 155.3, 149.8, 148.9, 135.7, 125.6, 123.9, 101.7, 92.9, 18.0. Anal. Calcd. for C₉H₇N₃O₂ (189.17) C 57.14, H 3.73, N 22.21. Found: C 56.76, H 3.41, N 21.62%.

7-Substituted furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-ones (6a-6c**).** Furo[2',3':4,5]-pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one **5a** (1.5 g, 8 mmol) was suspended in dimethylformamide (15 mL) and sodium hydride (0.42 g, 17 mmol) was added under stirring. After 15 min, appropriate alkyl halide (CH₃I, n-C₄H₉Br, PhCH₂Br) (14 mmol) was added dropwise and stirring was continued for 2.5h at room temperature (for PhCH₂Br overnight at 55 °C). The mixture was then poured into ice water and the precipitate was filtered off and crystallized from ethanol to obtain **6a-6c** as white solids.

7-Methylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (6a). Yield 72%, mp 210-214 °C; IR (KBr) ν/cm^{-1} 1641 (C=O). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.81 (d, 1H, *J* 0.6 Hz, H-5), 7.99 (d, 1H, *J* 2.4 Hz, H-2), 7.14 (s, 1H, H-9), 7.09 (dd, 1H, *J* 2.1, 0.9 Hz, H-3), 3.56 (s, 3H, CH₃); ^{13}C NMR (75 MHz, DMSO-*d*₆) δ 154.6, 149.9, 149.2, 127.8, 124.9, 123.8, 100.6, 93.0, 37.4. Anal. Calcd. for C₉H₇N₃O₂ (189.17) C 57.14, H 3.73, N 22.21. Found: C 57.33, H 3.82, N 22.11%.

7-Butylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (6b). Yield 47%, mp 115-118 °C; IR (KBr) ν/cm^{-1} 1643 (C=O). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.82 (d, 1H, *J* 0.9 Hz, H-5), 7.99 (d, 1H, *J* 2.4 Hz, H-2), 7.13 (d, 1H, *J* 0.3 Hz, H-9), 7.09 (dd, 1H, *J* 2.4, 0.9 Hz, H-3), 3.99 (t, 2H, CH₂), 1.73 (sextet, 2H, CH₂), 1.37 (sextet, 2H, CH₂), 0.93 (t, 3H, CH₃); ^{13}C NMR (75 MHz, DMSO-*d*₆) δ 154.3, 150.0, 149.3, 128.0, 124.9, 123.8, 100.6, 93.3, 48.3, 30.5, 19.7, 14.1. MS (ES): *m/z* 232.2 (MH⁺). Anal. Calcd. for C₁₂H₁₃N₃O₂ (231.26) C 62.33, H 5.67, N 18.17. Found: C 61.89, H 5.56, N 18.18%.

7-Benzylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (6c). Yield 27%, mp 184-188 °C; IR (KBr) ν/cm^{-1} 1641 (C=O). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.83 (s, 1H, H-5), 8.01 (d, 1H, *J* 2.1 Hz, H-2), 7.33-7.27 (m, 5H, Ph), 7.19 (s, 1H, H-9), 7.09 (dd, 1H, *J* 2.1, 0.9 Hz, H-3), 5.17 (s, 2H, CH₂); ^{13}C NMR (75 MHz, DMSO-*d*₆) δ 153.9, 149.7, 148.7, 137.3, 128.3, 127.8, 127.6, 127.6, 127.3, 127.3, 124.2, 123.5, 100.1, 93.2, 51.6. Anal. Calcd. for C₁₅H₁₁N₃O₂ (265.27) C 67.92, H 4.18, N 15.84. Found: C 68.19, H 4.32, N 16.24%.

Methyl {8-oxofuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-7(8*H*)-yl}acetate (6d). A solution of furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one **5a** (1.0 g, 6.0 mmol) in dimethylformamide (18 mL) was added to the suspension of NaH (0.21 g, 8.55 mmol) in dimethylformamide (16 mL). After stirring at room temperature for 30 min, the mixture was cooled to 0 °C and the methyl chloroacetate (1.54 g, 14.3 mmol) was added dropwise. The mixture was stirred at room temperature for 6h and then poured into ice water (30 mL), the precipitate was filtered off and crystallized from ethanol to give **6d** as white solid. Yield 45%, mp 175-180 °C; IR (KBr) ν/cm^{-1} 1736, 1650 (C=O). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.83 (d, 1H, *J* 0.9 Hz, H-5), 8.01 (d, 1H, *J* 2.4 Hz, H-2), 7.20 (d, 1H, *J* 0.6 Hz, H-9), 7.09 (dd, 1H, *J* 2.4, 0.6 Hz, H-3), 4.77 (s, 2H, CH₂), 3.67 (s, 3H, CH₃); ^{13}C NMR (75 MHz, DMSO-*d*₆) δ 168.2, 153.7, 149.7, 148.3, 127.5, 123.6, 123.5, 99.8, 93.2, 51.7, 50.1. Anal. Calcd. for C₁₁H₉N₃O₄ (247.21) C 53.44, H 3.67, N 17.00. Found: C 52.77, H 4.02, N 17.79%.

7-Acetylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one (6e). A solution of furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one **5a** (1.1 g, 6.3 mmol) in acetic anhydride (15 mL) was refluxed for 1.5 h. After cooling, the solid precipitate was filtered off and crystallized from acetone to obtain **6e** as white solid. Yield 53%, mp 242-245 °C; IR (KBr) ν/cm^{-1} 1745, 1662 (C=O). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.83 (d, 1H, *J* 0.3 Hz, H-5), 8.09 (d, 1H, *J* 2.4 Hz, H-2), 7.39 (t, 1H, *J* 0.6 Hz, H-9), 7.11 (dd, 1H, *J* 2.1, 0.9 Hz, H-3), 2.59 (s, 3H, CH₃); ^{13}C NMR (DMSO-*d*₆) δ 170.6, 154.4, 151.6, 149.2, 128.6, 125.7, 124.3, 100.7, 97.6, 26.9. Anal. Calcd. for C₁₀H₇N₃O₃ (217.18) C 55.30, H 3.25, N 19.35. Found: C 55.01, H 3.31, N 19.64%.

Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine-8(7*H*)-thione (7).¹⁵ A mixture of compound **5a** (1.5 g, 8.5 mmol) and P₂S₅ (1.9 g, 8.5 mmol) was stirred and refluxed in pyridine (8.6 mL) for 5h. The mixture was poured into hot water (30 mL) and the precipitate was filtered off and crystallized from dioxane to give **7** as pale brown solid. Yield 85%, mp 268-270 °C; IR (KBr) ν/cm^{-1} 3126 (NH), 1257(C=S); ^1H NMR (300 MHz, DMSO-*d*₆) δ 13.29 (s, 1H, NH), 9.16 (d, 1H, *J* 0.6 Hz, H-5), 8.09 (d, 1H, *J* 2.1 Hz, H-2), 7.29 (d, 1H, *J* 2.4 Hz, H-9), 7.15 (dd, 1H, *J* 2.1, 0.9 Hz, H-3); ^{13}C NMR (75 MHz, DMSO-*d*₆) δ 173.1, 150.5, 149.4, 131.7, 130.5, 123.9, 100.2, 95.3. MS (ESI⁺): *m/z* 192.1 (MH⁺). Anal. Calcd. for C₈H₅N₃OS (191.21) C 50.25, H 2.64, N 21.98, S 16.77. Found: C 50.48, H 2.62, N 22.14, S 16.89%.

7-Methylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine-8(7*H*)-thione (8a). **Method A:** Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazine-8(7*H*)-thione **7** (0.3 g, 1.6 mmol) was suspended in dimethylformamide (3 mL) and sodium

hydride (0.07 g, 3.1 mmol) was added under stirring at room temperature for 1h. Methyl iodide (0.44 g, 3.1 mmol) was added dropwise and stirring was continued for 4 h. The mixture was then poured into ice water (30 mL), the precipitate was filtered off and crystallized from dimethylformamide to give **8a** as yellow solid.

Method B: The mixture of 7-methylfuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-8(7*H*)-one **6a** (1g, 5.7 mmol) and P₂S₅ (1.27 g, 5.7 mmol) was stirred and refluxed in pyridine (10 mL) for 5h. The mixture was poured into hot water (20 mL) and extracted with chloroform (2x10 mL). Organic layer was separated, dried (Na₂SO₄) and the solvent was evaporated. The work-up was the same as in Method A. Yield 76% (A), 67% (B), mp >360 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.95 (s, 1H, H-5), 8.31 (d, 1H, *J* 2.4 Hz, H-2), 7.76 (s, 1H, H-9), 7.34 (dd, 1H, *J* 2.4, 0.9 Hz, H-3), 4.17 (s, 3H, CH₃); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 162.3, 157.7, 156.5, 144.8, 130.9, 125.9, 106.1, 99.7, 51.8. Anal. Calcd. for C₉H₇N₃OS (205.24) C 52.67, H 3.44, N 20.47, S 15.62. Found: C 52.91, H 3.49, N 20.58, S 15.88%.

Methyl (8-thioxofuro[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazin-7(8*H*)-yl)acetate (8b). The mixture of compound **6d** (2.47 g, 10 mmol) and P₂S₅ (2.67g, 12 mmol) was stirred and refluxed in pyridine (14 mL) for 9 h. The mixture was poured into hot water (20 mL), the precipitate was filtered off and crystallized from dioxane to give **8b** as yellow solid. Yield 71%, mp 168-172 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.25 (s, 1H, H-5), 8.11 (d, 1H, *J* 2.4 Hz, H-2), 7.36 (s, 1H, H-9), 7.15 (dd, 1H, *J* 2.4, 0.9 Hz, H-3), 5.32 (s, 2H, CH₂), 3.57 (s, 3H, CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.3, 167.4, 150.9, 131.6, 130.6, 127.9, 100.4, 96.8, 93.6, 56.7, 52.3. Anal. Calcd. for C₁₁H₉N₃O₃S (263.27) C 50.18, H 3.45, N 15.96, S, 12.18. Found C 49.97, H 3.56, N 14.32, S 12.06%.

2*H*-Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazino[3,4-*f*][1,2,4]triazine-3(4*H*)-one (9). Hydrazine hydrate (6 g, 120 mmol) was added to the solution of **8b** (2.11 g, 8 mmol) in ethanol (9.5 mL) and the mixture was stirred 140 h under reflux. After cooling the solid was filtered off, washed with water and crystallized from dioxane to give **9** as yellow solid. Yield: 64%, mp 247-250 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.72 (s, 1H, NH), 8.79 (s, 1H, H-5), 8.01 (d, 1H, *J* 2.1 Hz, H-2), 7.17 (s, 1H, H-12), 7.11 (dd, 1H, *J* 2.4, 0.9 Hz, H-3), 4.55 (s, 2H, CH₂). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 160.3, 154.3, 149.8, 147.9, 127.8, 124.5, 100.1, 93.1, 90.2, 50.3. Anal. Calcd. for C₁₀H₇N₅O₂ (229.20) C 52.40, H 3.08, N 30.56. Found C 52.09, H 3.13, N 30.78%.

Determination of Minimal Inhibition Concentration (MIC) parameters. On determination of MIC parameters there were used sterile microplates (type P), where the suspension of bacterial species in nutrient broth medium with dissolved tested compound has been achieved by convenient dilution method using automatic multichannel pipets. The concentration from the column 1 to column 12 was in the decreasing order: 20.48 mM; 10.24 mM; 5.12 mM; 2.56 mM; 1.28 mM; 0.64 mM; 0.32 mM; 0.16 mM; 0.08 mM; 0.04 mM; 0.02 mM and 0.01 mM. The inoculum concentration of bacterial species suspension in nutrient broth medium was before filling set by McFarland Densitometer DEN-1 (UK) on the value 0.1. The first two rows **A** and **B** were occupied by the standard 6-aminopenicilanic acid (6-APA) on each microplate and the tested compounds were in the rows **C-G**.

After 24h of cultivation at 37 °C in the bacteriological thermostat 30 µl of 0.03% solution of Thiazolyl Blue (MTT) in water was added to each well and incubated again for 1h under the same conditions. Bacterial proliferation led to the production of bacterial mitochondrial dehydrogenase, which turned yellow colored solution of MTT to intensively blue colored formazan product. MIC parameter was identified visually as the last not colored well in the row. All experiments were carried out as triplicate.

Acknowledgements

This work was supported by the Slovak Research Agency under the contracts No. VEGA 1/0534/16 and VEGA 1/0634/13.

<http://dx.doi.org/>

References

1. Krutošíková, A.; Dandárová, M.; Chylová, J.; Vegh, D. *Monatsh. Chem.* 1992, **123**, 807-815.
<http://dx.doi.org/10.1007/BF00812330>
2. Beccalli, E. M.; Broggin, G.; Martinelli, M.; Sottocornola, S. *Synthesis* **2008**, 136-140.
<http://dx.doi.org/10.1055/s-2007-990947>
3. Zhao, H.; Koenig, S. G.; Dankwardt, J. W.; Singh, S. P. *Org. Process Res. Dev.* **2014**, *18*, 198-204.
<http://dx.doi.org/10.1021/op4001737>
4. Raffa, D.; Maggio, B.; Raimondi, V. M.; Cascioferro, S.; Plescia, F.; Cancemi, G.; Daidone, G. *Eur. J. Med. Chem.* **2015**, *97*, 732-746.
<http://dx.doi.org/10.1016/j.ejmech.2014.12.023>
5. Sparey, T.; Abeywickrema, P.; Almond, S.; Brandon, N.; Byrne, N.; Campbell, A.; Hutson, P. H.; Jacobson, M.; Jones, B.; Munshi, S.; Pascarella, D.; Pike, A.; Prasad, G. S.; Sachs, N.; Sakatis, M.; Sardana, V.; Venkatraman, S.; Young, M. B. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3386-3391.
<http://dx.doi.org/10.1016/j.bmcl.2008.04.020>
6. Kawasima, Y.; Amanuma, F.; Sato, M.; Okuyama, S.; Nakashima, Y.; Sota, K.; Moriguchi, I. *J. Med. Chem.* **1986**, *29*, 2284-2290.
<http://dx.doi.org/10.1021/jm00161a026>
7. Zhuang, H. S.; Lin, Ch. Y.; Chou, Ch. L.; Hsu, H. M.; Lin, Y. H.; Huang, H. Ch.; Lien, Ch. J.; Kuo, CH. S.; Huang, J. L. *Eur. J. Med. Chem.* **2013**, *66*, 466-479.
<http://dx.doi.org/10.1016/j.ejmech.2013.06.012>
8. Umezawa, K.; Nakamura, Y.; Makino, H.; Citterio, D.; Suzuki, K. *J. Am. Chem. Soc.* **2008**, *130*, 1550-1551.
<http://dx.doi.org/10.1021/ja077756j>
9. Issartel, V.; Spohner, V.; Coudert, P.; Seilles, E.; Couquelet, J. *Bioorg. Med. Chem.* **1998**, *6*, 349-354.
[http://dx.doi.org/10.1016/S0968-0896\(97\)10052-9](http://dx.doi.org/10.1016/S0968-0896(97)10052-9)
10. Astakhina, V.; Voievudskiy, M.; Kharchenko, O.; Novikov, V.; Komarovska-Porohnyavets, E.; Petukhova, O. *J. Heterocycl. Chem.* **2016**, *53*, 421-428.
<http://dx.doi.org/10.1002/jhet.2204>
11. George, D. M.; Breinlinger, E. C.; Friedman, M.; Zhang, Y.; Wang, J.; Argiriadi, M.; Bansal-Pakala, P.; Barth, M.; Duignan, D. B.; Honore, P.; Lang, Q.; Mittelstadt, S.; Potin, D.; Rundell, L.; Edmunds, J. J. *J. Med. Chem.* **2015**, *58*, 222-236.
<http://dx.doi.org/10.1021/jm500669m>
12. Schoenfeld, R. C.; Bourdet, D. L.; Brameld, K. A.; Chin, E.; De Vicente, J.; Fung, A.; Harris, S. F.; Lee, E. K.; Le Pogam, S.; Leveque, V.; Li, J.; Lui, A. S.-T.; Najera, I.; Rajyaguru, S.; Sangi, M.; Steiner, S.; Talamas, F. X.; Taygerly, J. P.; Zhao, J. *J. Med. Chem.* **2013**, *56*, 8163-8182.
<http://dx.doi.org/10.1021/jm401266k>

13. Zhan, P.; Li, X.; Li, Z.; Chen, X.; Tian, Y.; Chen, W.; Liu, X.; Pannecoque, C.; De Clercq, E.: *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7155-7162.
<http://dx.doi.org/10.1016/j.bmcl.2012.09.062>
14. El-Gendy, A. A.; Said, M. M.; Ghareb, N.; Mostafa, Y. M.; El-Ashry, E. S. H. *Arch. Pharm.* **2008**, *341*, 294-300.
<http://dx.doi.org/10.1002/ardp.200700161>
15. Jiang, J.-k.; Boxer, M. B.; Vander Heiden, M. G.; Shen, M.; Skoumbourdis, A. P.; Southall, N.; Veith, H.; Leister, W.; Austin, C. P.; Park, H. W.; Inglese, J.; Cantley, L. C.; Auld, D. S.; Thomas, C. J. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3387-3393. DOI:10.1016/j.bmcl.2010.04.015
16. Krutošiková, A.; Kováč, J.; Dandárová, M. *Collect. Czech. Chem. Commun.* **1984**, *49*, 65-70.
<http://dx.doi.org/10.1135/cccc19840065>
17. Kudelko, A.; Zielinski, W.; Ejsmont, K.: *Tetrahedron*, **2011**, *67*, 7838-7845.
<http://dx.doi.org/10.1016/j.tet.2011.07.047>
18. Andersen, T. P.; Ghattas, A.-B. A. G.; Lawesson, S. O. *Tetrahedron*, **1983**, *39*, 3419-3427.
[http://dx.doi.org/10.1016/S0040-4020\(01\)91595-9](http://dx.doi.org/10.1016/S0040-4020(01)91595-9)
19. Gajdoš, P.; Pavlíková, S.; Bureš, F.; Krutošiková, A. *Cent. Eur. J. Chem.* **2005**, 311- 325.
<http://dx.doi.org/10.2478/BF02475999>
20. Krutošiková, A.; Kráľovičová, E.; Kováč, J.; Dandárová, M. *Collect. Czech. Chem. Commun.* **1986**, *51*, 1455-1461.
<http://dx.doi.org/10.1135/cccc19861455>
21. Lipinski, C. A.; Lombardo, F. ; Dominy, B.W. ; Feeney, P.J. *Adv. Drug Deliv. Rev.* **2001**, *46*, 3 -26.
[http://dx.doi.org/10.1016/S0169-409X\(00\)00129-0](http://dx.doi.org/10.1016/S0169-409X(00)00129-0)
22. Lipinski, C. A. *Drug Discov. Today: Technol.* **2004**, *1*, 337–341.
<https://doi.org/10.1016/j.ddtec.2004.11.007>